Hepatitis B and C infections represent the leading causes of liver cancer worldwide. These viruses gradually damage liver ...

The ageing and failure of cells that occurs when the liver is damaged can spread to other organs, suggests a new study in ...

Cirrhosis, hepatitis infection and other causes can trigger liver fibrosis -- a potentially lethal stiffening of tissue ...

Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to ...

A new study highlights how signals from the liver to the brain influence eating patterns tied to our circadian rhythms.

Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, ...

According to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver ...

Liver failure encompasses a range of severe clinical syndromes resulting from the deterioration of liver function, triggered ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis ...

Additionally, HMGB1 plays a role in autophagy, a process integral to cell survival and liver tissue regeneration. HMGB1's ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...